Georgetown University and Samaritan Sign Exclusive Licensing Agreement for Novel Treatment of Cushing's Syndrome
08. August 2007 09:52 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Aug. 8, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive licensing agreement with...
Samaritan's Chief Drug Development Officer to Present Lead Alzheimer's Drug At 12th IBC World Congress
02. August 2007 10:05 ET
|
Samaritan Pharmaceuticals, Inc.
Focus Area: New and Emerging Therapeutic Targets for CNS
Topic: SP-233: A New and Novel Therapy With Protective Properties Against
the Neurotoxic Effects of Beta-Amyloid Peptide
LAS VEGAS,...
Samaritan Exclusively Licenses Innovative Blood Diagnostic to Uncover Whether Breast Tumor is Cancer
30. Juli 2007 10:22 ET
|
Samaritan Pharmaceuticals, Inc.
Blood Test Can Detect One Single Aggressive Cancer Cell Out of
Millions of Normal Blood Cells
Diagnostic Technology Thought to Detect Prostrate and Colon
...
Samaritan Therapeutics Signs Research Collaboration and Licensing Agreement With The Research Institute of McGill University Health Centre
25. Juli 2007 10:01 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, July 25, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, and Samaritan Therapeutics, Canada, is pleased to announce it has signed a...
Samaritan Licenses Exclusive Rights to Infectious Disease Compounds From Georgetown University
24. Juli 2007 09:49 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, July 24, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today that it has entered into an exclusive license agreement with...
Samaritan Announces Positive Preliminary Results in a Phase IIb Study For Its Novel Oral HIV Entry Inhibitor
20. Juli 2007 07:00 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, July 20, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce its novel oral HIV entry inhibitor SP-01A, being...
Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease
10. Juli 2007 09:35 ET
|
Samaritan Pharmaceuticals, Inc.
Animal Study Confirms Caprospinol's (SP-233) Ability to Clear Brain
Plaque and Empower Rat Brain Cells to Recover Memory Function
In Vivo 'Proof of Concept' Study Proposes Direct Correlation...
Samaritan Reorganizes Its Stock Structure
28. Juni 2007 15:44 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, June 28, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative life-saving drugs, announced today its Board of Directors has unanimously decided to...
Nationally Recognized M.D. Joins Samaritan Pharmaceuticals' Board of Directors
12. Juni 2007 10:58 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, June 12, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative life saving drugs, announces Doug Bessert has decided for personal reasons to step...
Samaritan in Collaboration With UCSD Awarded NIH Grant for the Continued Development of Samaritan's Compounds to Suppress HIV Viral Replication and Prevent Neuronal Damage
07. Juni 2007 09:40 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, June 7, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce the National Institutes of Health (NIH) has awarded a...